^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    CD19-targeted CAR-T immunotherapy

    Related drugs:
    23h
    Study of Efficacy and Safety of CRC01 in Adult Large B-cell Lymphoma and B-cell Acute Lymphoblastic Leukemia Patients (clinicaltrials.gov)
    P1/2, N=91, Recruiting, Curocell Inc. | Trial completion date: Feb 2028 --> Sep 2030 | Trial primary completion date: May 2023 --> Aug 2030
    Trial completion date • Trial primary completion date
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV • Rimqarto (anbalcabtagene autoleucel)
    2d
    Atalanta-1: A Study Evaluating the Safety and Efficacy of GLPG5101 (19CP02) in Participants With Non-Hodgkin Lymphoma (clinicaltrials.gov)
    P1/2, N=130, Terminated, Lakefront Biotherapeutics NV | Trial completion date: Jul 2029 --> May 2026 | Active, not recruiting --> Terminated | Trial primary completion date: Jul 2029 --> May 2026; Following the decision by Galapagos NV to wind down its cell therapy programs, the study was early terminated at the end of the study treatment period for the last subject (27-May-2026).
    Trial completion date • Trial termination • Trial primary completion date
    2d
    Phase 1 Study Of KITE-753 in R/R B-Cell ALL (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, M.D. Anderson Cancer Center
    New P1 trial
    |
    CD20 (Membrane Spanning 4-Domains A1)
    |
    CD20 positive
    |
    clonoSEQ®
    2d
    Lymphodepletion With Low Dose Total Body Irradiation Before Standard of Care Tisagenlecleucel for the Treatment of Relapsed and Recurrent Large B-cell Lymphoma (clinicaltrials.gov)
    P1, N=18, Not yet recruiting, Nathan Denlinger
    New P1 trial
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • Kymriah (tisagenlecleucel-T) • fludarabine IV
    2d
    Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma (clinicaltrials.gov)
    P2, N=50, Recruiting, M.D. Anderson Cancer Center | Active, not recruiting --> Recruiting
    Enrollment open • Minimal residual disease
    |
    BCL2 (B-cell CLL/lymphoma 2)
    |
    Foresight CLARITY™
    |
    Breyanzi (lisocabtagene maraleucel)
    3d
    RD06-05 Universal CD19/BCMA CAR-T for Refractory Pediatric Autoimmune Diseases (clinicaltrials.gov)
    P1, N=30, Not yet recruiting, The Children's Hospital of Zhejiang University School of Medicine
    New P1 trial
    |
    cyclophosphamide • fludarabine IV
    6d
    An Exploratory Clinical Study of Anti-CD19 CAR NK Cell (KN5501) in the Treatment of Relapsed/Refractory Immune Nephropathy (clinicaltrials.gov)
    P1, N=36, Recruiting, Changhai Hospital | Trial completion date: Jun 2026 --> Jun 2027 | Trial primary completion date: Jun 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    CD19 (CD19 Molecule)
    |
    cyclophosphamide • fludarabine IV • KN5501
    6d
    GoFast CAR T-Cell Therapy for Recurrent Refractory B-Cell Lymphoma (clinicaltrials.gov)
    P1, N=9, Not yet recruiting, Chinese PLA General Hospital
    New P1 trial
    |
    CD19 positive
    |
    cyclophosphamide • fludarabine IV
    7d
    JKART-1: Study of KTE-X19 in Adult Japanese Participants With Relapsed/Refractory Mantle Cell Lymphoma or Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (clinicaltrials.gov)
    P2, N=25, Active, not recruiting, Kite, A Gilead Company | Trial primary completion date: Nov 2025 --> Jul 2027
    Trial primary completion date
    |
    CCND1 (Cyclin D1)
    |
    Chr t(11;14)
    |
    cyclophosphamide • fludarabine IV • Tecartus (brexucabtagene autoleucel)
    7d
    CAB-201-005: RESET-MS: A Study to Evaluate the Safety and Efficacy of CABA-201 in Participants With Multiple Sclerosis (clinicaltrials.gov)
    P1/2, N=0, Withdrawn, Cabaletta Bio | N=12 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    cyclophosphamide • fludarabine IV
    8d
    Ten-Year Outcomes after CAR T-Cell Therapy for B-Cell Lymphomas. (PubMed, N Engl J Med)
    Among patients with heavily pretreated B-cell non-Hodgkin lymphoma, a single infusion of tisagenlecleucel led to decade-long remissions (lymphoma-free survival) in approximately one third of the patients with large B-cell lymphomas and in nearly one half of those with follicular lymphoma. (Funded by the Richard Berman Family Innovations Center in CLL and Lymphomas and others; ClinicalTrials.gov number, NCT02030834.).
    Journal
    |
    CD19 (CD19 Molecule)
    |
    Kymriah (tisagenlecleucel-T)
    8d
    A Study of LCAR-AIO CAR-T Cells for Treating Relapsed/Refractory Neurological Autoimmune Diseases (clinicaltrials.gov)
    P1, N=0, Withdrawn, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | N=37 --> 0 | Recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    |
    LCAR-AIO